natgillin/translations-raw huggingface dataset:
Sprimeo HCT 150 mg/25 mg film-coated tablets are pale yellow, oval film-coated tablets imprinted with “CLL” on one side and “NVR” on the other. 
Filmsko obložene tablete Sprimeo HCT 150 mg/25 mg so bledo rumene ovalne filmsko obložene tablete z oznako “CLL” na eni strani in “NVR” na drugi.
Sprimeo HCT 150 mg/12.5 mg film-coated tablets 
Sprimeo HCT 150 mg/12,5 mg filmsko obložene tablete
OTHER 
Sprimeo
Sprimeo HCT 150 mg /12.5 mg may be administered in patients whose blood pressure is not adequately controlled with aliskiren 150 mg or hydrochlorothiazide 12.5 mg alone. 
Zdravilo Sprimeo HCT 150 mg/12,5 mg je mogoče uporabljati pri bolnikih, katerih krvni tlak ni ustrezno urejen, če uporabljajo samo aliskiren v odmerku 150 mg ali samo hidroklorotiazid v odmerku 12,5 mg.
Sprimeo HCT 300 mg/12.5 mg film-coated tablets are violet white, oval film-coated tablets imprinted with “CVI” on one side and “NVR” on the other. 
Filmsko obložene tablete Sprimeo HCT 300 mg/12,5 mg so vijoličasto bele ovalne filmsko obložene tablete z oznako “CVI” na eni strani in “NVR” na drugi.
Side effects reported in clinical studies for patients treated with Sprimeo HCT were: Common (affecting less than 1 in 10 patients): 
V kliničnih študijah so pri bolnikih, ki so prejemali zdravilo Sprimeo HCT, opisali naslednje neželene učinke:
- Each Sprimeo HCT 300 mg/25 mg film-coated tablet contains 300 mg aliskiren (as hemifumarate) and 25 mg hydrocholorothiazide. 
- Vsaka filmsko obložena tableta Sprimeo HCT 300 mg/25 mg vsebuje 300 mg aliskirena (v obliki hemifumarata) in 25 mg hidroklorotiazida.
Abdominal discomfort, constipation, diarrhoea 
bolečine v trebuhu, obstipacija, diareja zelo redki:
Sprimeo HCT 300 mg/25 mg film-coated tablets are light yellow, oval film-coated tablets imprinted with “CVV” on one side and “NVR” on the other. 
Filmsko obložene tablete Sprimeo HCT 300 mg/25 mg so svetlo rumene ovalne filmsko obložene tablete z oznako “CVV” na eni strani in “NVR” na drugi.
Always take Sprimeo HCT exactly as your doctor has told you. 
Pri jemanju zdravila Sprimeo HCT natančno upoštevajte zdravnikova navodila.
Sprimeo HCT 150 mg /25 mg may be administered in patients whose blood pressure is not adequately controlled with aliskiren 150 mg or hydrochlorothiazide 25 mg alone or by Sprimeo HCT 150 mg/12.5 mg. 
Zdravilo Sprimeo HCT 150 mg/25 mg je mogoče uporabljati pri bolnikih, katerih krvni tlak ni ustrezno urejen, če uporabljajo samo aliskiren v odmerku 150 mg ali samo hidroklorotiazid v odmerku 25 mg ali če uporabljajo zdravilo Sprimeo HCT 150 mg/12,5 mg.
Sprimeo HCT 300 mg/25 mg film-coated tablets Aliskiren/hydrochlorothiazide 
Sprimeo HCT 300 mg/25 mg filmsko obložene tablete aliskiren/hidroklorotiazid
Sprimeo HCT 150 mg/25 mg film-coated tablets Aliskiren/hydrochlorothiazide 
Sprimeo HCT 150 mg/25 mg filmsko obložene tablete aliskiren/hidroklorotiazid
Sprimeo HCT 300 mg /12.5 mg may be administered in patients whose blood pressure is not adequately controlled with aliskiren 300 mg or hydrochlorothiazide 12.5 mg alone or by Sprimeo HCT 150 mg/12.5 mg. 
Zdravilo Sprimeo HCT 300 mg/12,5 mg je mogoče uporabljati pri bolnikih, katerih krvni tlak ni ustrezno urejen, če uporabljajo samo aliskiren v odmerku 300 mg ali samo hidroklorotiazid v odmerku 12,5 mg ali če uporabljajo zdravilo Sprimeo HCT 150 mg/12,5 mg.
HOW TO STORE SPRIMEO HCT 
SHRANJEVANJE ZDRAVILA SPRIMEO HCT
Sprimeo HCT 300 mg/12.5 mg film-coated tablets Aliskiren/hydrochlorothiazide 
Sprimeo HCT 300 mg/12,5 mg filmsko obložene tablete aliskiren/hidroklorotiazid
Sprimeo HCT 150 mg/12.5 mg film-coated tablets Aliskiren/hydrochlorothiazide 
Sprimeo HCT 150 mg/12,5 mg filmsko obložene tablete aliskiren/hidroklorotiazid
The use of aliskiren in combination with ARBs or ACEIs is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see section 4.3). 
Sočasna uporaba zdravila Sprimeo HCT in zaviralcev angiotenzinskih receptorjev II ali zaviralcev ACE je kontraindicirana pri bolnikih z okvaro ledvic (GFR < 60 ml/min/1,73 m2) (glejte poglavje 4.3).
Sprimeo HCT is contraindicated in patients with anuria or severe renal impairment (GFR < 30 ml/min/1.73 m2) and the concomitant use of Sprimeo HCT with ARBs or ACEIs is contraindicated in patients with renal impairment (GFR < 60 ml/min/1.73 m 
Pri bolnikih z okvaro ledvic (GFR < 60 ml/min/1,73 m2) je sočasna uporaba aliskirena in zaviralcev ACE ali zaviralcev angiotenzinskih receptorjev II kontraindicirana.
Concomitant use of Sprimeo HCT with ARBs or ACEIs is contraindicated in patients with diabetes mellitus (see section 4.3). 
SprimeoPri bolnikih s sladkorno boleznijo je sočasna uporaba zdravila Sprimeo HCT in zaviralcev angiotenzinskih receptorjev II ali zaviralcev ACE kontraindicirana (glejte poglavje 4.3).
Reproductive system and breast disorders Common: 
Bolezni mišično-skeletnega sistema in vezivnega tkiva pogosti:
Impotence General disorders and administration site conditions Not known: 
Splošne težave in spremembe na mestu aplikacije občasni:
Sprimeo HCT should be discontinued if hypercalcaemia develops during treatment. 
Če pride med zdravljenjem do razvoja hiperkalciemije, je treba uporabo zdravila Sprimeo HCT prekiniti.
- alcohol, sleeping pills and anaesthetics (medicines allowing patients to undergo surgery and other procedures). 
- holestiramin, holestipol ali druge izmenjevalne smole (snovi, ki jih uporabljamo predvsem za zdravljenje visokih ravni lipidov v krvi), - citotoksična zdravila (za zdravljenje raka), kot sta metotreksat ali ciklofosfamid, - mišičnih relaksantov (zdravil za sproščanje mišic, ki jih uporabljajo med operacijami), - alkohol, uspavalne tablete in anestetike (zdravila, ki omogočajo bolnikom, da prestanejo operacije in druge posege), - jodirana kontrastna sredstva (sredstva, ki jih uporabljajo pri slikovnih preiskavah), - zdravila za artritis.
The concomitant use of aliskiren and ACEIs or ARBs is contraindicated in patients with renal impairment (GFR < 60 ml/min/1.73 m2). 
Zdravilo Sprimeo HCT kontraindicirano pri bolnikih z anurijo in pri bolnikih s hudo okvaro ledvic (s GFR < 30 ml/min/1,73 m2).
Immune system disorders Rare: 
Srčne bolezni redki:
Renal dysfunction, acute renal failure 
akutni glavkom zaprtega zakotja
(It is also better to avoid Sprimeo HCT in early pregnancy - see Pregnancy section.) 
Uporaba zdravila Sprimeo HCT ni priporočljiva v zgodnjem obdobju nosečnosti.
CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES 
DODATEK POGOJI ALI OMEJITVE GLEDE VARNE IN UČINKOVITE UPORABE ZDRAVILA, KI NAJ JIH UVELJAVIJO DRŽAVE ČLANICE
• Prior to launch of the product in the Member State, the national competent authority shall agree the content and format of the educational material with the Marketing Authorisation Holder 
• Pred uvedbo zdravila na trg v državi članici mora nacionalni pristojni organ uskladiti vsebino in obliko izobraževalnega gradiva z imetnikom dovoljenja za promet z zdravilom.
• The Marketing Authorisation Holder (MAH) should ensure that, at launch, all Healthcare Professionals who are expected to prescribe Cinryze are provided with an Educational pack. 
• Imetnik dovoljenja za promet z zdravilom (MAH) mora zagotoviti, da bodo ob uvedbi zdravila na trg vsi zdravstveni delavci, za katere se pričakuje, da bodo predpisovali zdravilo Cinryze, prejeli izobraževalni paket.
The Member States must ensure that all conditions or restrictions with regard to the safe and effective use of the medicinal product described below are implemented in their national territory: 
Države članice morajo zagotoviti, da bodo na njihovem nacionalnem ozemlju uveljavljeni vsi pogoji ali omejitve glede varne in učinkovite uporabe zdravila, opisane v nadaljevanju:
The existence of a post marketing registry in which health care professionals are encouraged to enter patients 
Obstoj postmarketinškega registra, v katerega zdravstveni delavci vpisujejo bolnike, k čemur jih spodbujamo.
• Educational material for Healthcare Professionals 
• Izobraževalno gradivo za zdravstvene delavce;
The educational pack should contain the following: 
Izobraževalni paket naj vsebuje naslednje:
• Summary of Product Characteristics and Patient Information Leaflet for Cinryze 
• Povzetek glavnih značilnosti zdravila in navodilo za uporabo zdravila Cinryze;
Their prescribing physician will provide training on the following elements: Precaution for storage 
Njihov zdravnik, ki predpisuje zdravilo, bo poskrbel za izobraževanje o naslednjih elementih: Navodila za shranjevanje,
• Educational materials for non Healthcare Professionals 
• Izobraževalna gradiva za osebe, ki niso zdravstveni delavci.
The educational material for non Healthcare Professionals should include information on the following key elements: 
Izobraževalno gradivo za osebe, ki niso zdravstveni delavci, naj obsega informacije o naslednjih ključnih elementih:
Necessary skills have to be acquired by non-healthcare professionals before Cinryze may be safely and effectively administered at home. 
Osebe, ki niso zdravstveni delavci, si morajo pridobiti potrebno znanje, preden se lahko zdravilo Cinryze varno in učinkovito uporablja doma.
A leaflet providing detailed information on the key elements of the training that should be kept at home for further reference. 
Navodilo s podrobnostmi ključnih elementov izobraževanja, ki naj ga bolnik hrani doma zaradi nadaljnjih napotkov.
The educational material for Healthcare Professionals should include information on the following key elements: 
Izobraževalno gradivo za zdravstvene delavce mora vključevati informacije o naslednjih ključnih elementih:
For some patients the prescribing physician may decide that Cinryze may be administered at home by a non Healthcare Professional such as a family member or by self-administration. 
Zdravnik, ki predpisuje zdravilo, se lahko odloči, da nekaterim bolnikom lahko daje zdravilo Cinryze doma oseba, ki ni zdravstveni delavec, na primer družinski član, ali da si lahko dajejo zdravilo bolniki sami.
London, 23 January 2008 EMEA/CHMP/350278/2007 
London, 23. januar 2008 EMEA/CHMP/350278/2007
The Reference Member State was United Kingdom and the Concerned Member States were Denmark, Finland, Norway and Sweden. 
Referenčna država članica je bilo Združeno kraljestvo, zadevne države članice pa so bile Danska, Finska, Norveška in Švedska.
Article 29(4) of Directive 2001/83/EC, as amended. 
Člen 29 (4) direktive 2001/83/ES, z vsemi spremembami.
The Mutual Recognition Procedure started on 15 November 2005. 
Postopek medsebojnega priznavanja se je začel 15. novembra 2005.
These issues were considered to be of serious public health concern. 
Menili so, da ta sporna vprašanja predstavljajo resen zadržek glede javnega zdravja.
The Rapporteur was Dr Hudson and Co-Rapporteur(s) was Dr Ljungberg. 
Poročevalec je bil dr. Hudson, soporočevalec pa dr. Ljungberg.
The final opinion was converted into a Decision by the European Commission on 18 January 2008. 
Končno mnenje je bilo spremenjeno v odločbo Evropske komisije dne 18. januarja 2008.
International Non-Proprietary Name (INN): Ciprofloxacin 
Mednarodno nelastniško ime (INN): Ciprofloxacin
The arbitration procedure started on 1 June 2006 with the adoption of a list of questions. 
Arbitražni postopek se je začel 1. junija 2006 s sprejemom seznama vprašanj.
These Member States were not able to reach an agreement with respect to the Mutual Recognition of the Marketing Authorisation granted by the Reference Member State. 
Omenjene države članice niso mogle doseči soglasja glede skupnega priznavanja dovoljenja za promet, ki ga je izdala referenčna država članica.
United Kingdom referred the reasons for disagreement to the EMEA on 5 May 2006. 
Združeno kraljestvo je dne 5. maja 2006 agenciji EMEA podalo razloge za nesoglasje.
Ciprofloxacin Nycomed and associated names 
Ciprofloxacin Nycomed in z njim povezana imena
The Marketing Authorisation Holder provided written explanations on 21 September 2006. 
Imetnik dovoljenja za promet z zdravilom je pisna pojasnila predložil dne 21. septembra 2006.
A positive opinion was adopted by consensus on 16 November 2006. 
Odbor je dne 16. novembra 2006 soglasno sprejel pozitivno mnenje.
The list of the product names concerned is given in Annex I. The scientific conclusions are provided in Annex II, together with the Summary of Product Characteristics in Annex III. 
Seznam zadevnih imen zdravil je podan v dodatku I. Znanstveni zaključki so na voljo v dodatku II, povzetek glavnih značilnosti zdravila pa v dodatku III.
Ciprofloxacin Nycomed and associated names, 2 mg/ml Solution for Infusion, is an antibiotic belonging to the quinolone family effective in vitro against a large number of Gram-negative aerobic bacteria as well as against some Gram-positive organisms. 
Ciprofloxacin Nycomed in z njim povezana imena, 2 mg/ml raztopina za infundiranje, je antibiotik iz družine kinolonov, ki so in vitro učinkoviti proti mnogim po Gramu negativnim aerobnim bakterijam kot tudi nekaterim po Gramu pozitivnim organizmom.
The proposed dosage regimen for complicated urinary tract infections (100 mg bid) was considered too low and should be changed to 200-400 mg twice daily. 
Predlagani režim odmerjanja pri zapletenih okužbah sečil (100 mg bid) je domnevno prenizek in bi ga bilo treba spremeniti v 200-400 mg dvakrat dnevno.
Further, as patients referred to parenteral treatment often are seriously ill, it was felt of importance that a maximum dosage of 1200 mg (400 mg three times daily) instead of 800 mg be permitted. 
Prav tako bi moral zaradi resnosti bolezni tistih bolnikov, ki se zdravijo s parenteralnim načinom zdravljenja, najvišji dovoljeni odmerek zdravila znašati 1200 mg (400 mg trikrat dnevno) namesto 800 mg.
During their 13-16 November 2006 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/risk ratio is favourable for Ciprofloxacin Nycomed and associated names, that the objections raised by Norway and Sweden should not prevent the granting of a Marketing Authorisation and that the Summary of Product Characteristics, labelling and package leaflet of the Reference Member State should be amended. 
Med svojim zasedanjem od 13. do 16. novembra 2006 je CHMP na podlagi vseh predloženih podatkov in znanstvene razprave v okviru odbora zaključil, da je razmerje med koristmi in tveganji za zdravilo Ciprofloxacin Nycomed in z njim povezana imena ugodno, ter da ugovori, ki sta jih imeli Norveška in Švedska, ne bi smeli preprečiti izdaje dovoljenja za promet z zdravilom in da je treba dopolniti povzetek glavnih značilnosti zdravila, označevanje in navodilo za uporabo.
Nycomed Danmark ApS submitted applications for mutual recognition of Ciprofloxacin Nycomed and associated names, 2 mg/ml Solution for Infusion, on the basis of the marketing authorisation granted by United Kingdom on 23 March 2005. 
Družba Nycomed Danmark ApS je predložila vloge za medsebojno priznavanje zdravila Ciprofloxacin Nycomed in z njim povezanih imen, 2 mg/ml raztopine za infundiranje, na osnovi dovoljenja za promet z zdravilom, ki ga je izdalo Združeno kraljestvo dne 23. marca 2005.
On 21 June 2007 the CHMP, in order to focus and facilitate the translations of the specific amendments in the Summary of Product Characteristics, adopted a revised opinion with amended Annex II and Annex III, which was further reconsidered in October 2007. 
Dne 21. junija 2007 je CHMP izdal spremenjeno mnenje z dopolnjenim dodatkom II in dodatkom III, da bi tako olajšal prevajanje določenih sprememb v povzetku glavnih značilnosti zdravila, kar je odbor znova pretehtal oktobra 2007.
Significant differences were identified with regards to the approved posology for complicated urinary tract infections and the maximum daily dose for this generic intravenous ciprofloxacin product. 
Pri odobrenem režimu odmerjanja v primeru zapletenih okužb sečil in največjem dnevnem odmerku tega intravenoznega generika ciprofloksacina so bile opažene znatne razlike.
This is normal, they will not harm you. 
To je normalno in ne bodo vam škodovali.
• You are elderly. 
• ste starejši,
The end of the observation period was 36 hours. 
Obdobje opazovanja se je končalo po 36 urah.
Ask your doctor whether you can drive if: 
Zdravnika vprašajte, ali lahko vozite, če:
Be especially aware of the following: 
Bodite posebej pozorni na naslednje:
• Sugar (at least 20 grams). 
• sladkor (vsaj 20 gramov).
ATC Code: A10A E04. 
Oznaka ATC: A10A E04.
• How much Toujeo you need each day and at what time. 
• koliko zdravila Toujeo potrebujete na dan in ob katerem času,
• When you may need a higher or lower dose. 
• kdaj boste morda potrebovali večji ali manjši odmerek.
• Your insulin has become less effective - for example because it was not stored properly. 
• Insulin je postal manj učinkovit - na primer zato, ker ni bil pravilno shranjen.
• You drink alcohol - especially when you have not eaten much. 
• Pijete alkohol - zlasti če niste dovolj jedli.
This is especially important if you have other injector pens. 
To je še posebno pomembno, če uporabljate še druge injekcijske peresnike.
Details for national reporting added at country level; 
Podrobnosti o nacionalnem poročanju bodo dodane na ravni držav;
*RR: estimated risk ratio; [95% Confidence Interval] 
*RT: ocenjeno razmerje tveganj [95 % interval zaupanja]
This must always be treated by a doctor, normally in a hospital. 
Vedno vas mora zdraviti zdravnik, praviloma v bolnišnici.
• You have had diabetes for a long time. 
• imate sladkorno bolezen že dolgo časa,
• You have recently had too low blood sugar (for example the day before). 
• ste nedavno imeli prenizek krvni sladkor (na primer prejšnji dan),
You also need to be careful when you stop taking a medicine. 
Previdni morate biti tudi tedaj, ko nehate jemati kakšno zdravilo.
• Information so that others know you have diabetes. 
• ustrezne informacije, tako da drugi vedo, da imate sladkorno bolezen.
These injections should be given even if it is not certain that you have hypoglycaemia. 
Te injekcije je treba dati, tudi če ni gotovo, da imate hipoglikemijo.
• Sulfonamide antibiotics. 
• Sulfonamidne antibiotike.
The target audience and the modalities for distribution of all of these materials are to be agreed at Member State Level. 
Glede ciljnih skupin in načina razdeljevanja vseh teh gradiv se je treba dogovoriti na ravni države članice.
If the hypoglycaemia comes back again, take another 10 to 20 grams of sugar. 
Če se hipoglikemija znova pojavi, zaužijte dodatnih 10 do 20 gramov sladkorja.
• The possible effects of changing to different time zones. 
• O možnih vplivih spremembe časovnih con.
If you have “Type 1” diabetes and you have an illness or injury: 
Če imate sladkorna bolezen "tipa 1" in imate kakšno bolezen ali poškodbo:
• This will make sure you get your full dose. 
• Tako boste zagotovili, da boste dobili poln odmerek.
Long term efficacy and safety outcome study 
Študija dolgotrajnih izidov učinkovitosti in varnosti
If you find it difficult to recognise your warning signs, you should avoid situations (such as driving a car) in which you or others would be put at risk by hypoglycaemia. 
Če težko prepoznate svoje opozorilne znake, se morate izogibati okoliščinam (npr. vožnji avta), v katerih bi zaradi hipoglikemije ogrožali sebe ali druge.
See also section 4.2 under “Method of administration”. 
Glejte tudi poglavje 4.2, naslov "Način uporabe".
• What you should do in an emergency situation if you feel unwell or become ill. 
• Kako ukrepati v nujnih primerih, če se ne počutite dobro ali če zbolite.
Date of first authorisation: 27 June 2000 Date of latest renewal: 17 February 2015 
Datum zadnjega podaljšanja: 17. februar 2015
Take about 10 to 20 grams sugar straight away - such as glucose, sugar cubes or a sugary-drink. 
Takoj zaužijte od 10 do 20 gramov sladkorja - na primer glukozo, kocke sladkorja ali kakšno sladko pijačo.
The educational materials for healthcare professionals shall contain the following key elements: 
Izobraževalno gradivo za zdravstvene delavce mora vsebovati naslednje ključne elemente:
It is used for once daily dosing. 
Namenjen je uporabi enkrat na dan.
• Keep eating enough carbohydrates. 
• Še naprej uživajte dovolj ogljikovih hidratov.
• You have a certain type of nervous disease (called “diabetic autonomic neuropathy”). 
• imate določeno vrsto bolezni živčevja (imenovano "diabetična avtonomna nevropatija"),
See the section below for help. 
Za pomoč glejte poglavje , spodaj.
In the following situations, the management of your diabetes may require extra care (for example, blood and urine tests): 
V naslednjih okoliščinah lahko vodenje sladkorne bolezni zahteva dodatno skrb (na primer teste krvi in urina):
Results from a study on progression of diabetic retinopathy 
Rezultati študije o napredovanju diabetične retinopatije
Then remove the needle from your skin. 
Potem potegnite iglo iz kože.
• You are under stress - such as emotional distress or excitement. 
• Ste pod stresom - na primer v čustveni stiski ali razburjeni.
E After holding and slowly counting to 5, release the injection button. 
E Potem, ko ste gumb držali in počasi prešteli do 5, gumb za injiciranje spustite.
For single patient use only. 
Izključno za uporabo pri enem samem bolniku.
Always tell people who are caring or treating you, that you have diabetes. 
Ljudem, ki za vas skrbijo ali vas zdravijo, vedno povejte, da imate sladkorno bolezen.
Do not drink or eat foods that contain artificial sweeteners (such as diet drinks). 
Ne pijte pijač in ne jejte živil, ki vsebujejo umetna sladila (npr. dietne pijače).
ANNEX II A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT 
PRILOGA II A. PROIZVAJALEC BIOLOŠKE UČINKOVINE IN PROIZVAJALCI, ODGOVORNI ZA SPROŠČANJE SERIJ B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM D. POGOJI ALI OMEJTIVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA
• Danazol - for endometriosis. 
• Danazol - za endometriozo.
This means it is essentially ‘sodium-free'. 
To pomeni, da je praktično "brez natrija".
• The time you eat meals and use your insulin. 
• Glede časa, ko uživate obroke in uporabljate insulin.
• Your low blood sugar is always around “normal” or your blood sugar has got much better. 
• je vaš nizki krvni sladkor vedno blizu "normalnega" ali se vam je krvni sladkor močno izboljšal.
Needles must be discarded immediately after use. 
Igle je treba takoj po uporabi zavreči.
• If you cannot select your full prescribed dose, split the dose into two injections or use a new pen. 
• Če ne morete izbrati celotnega predpisanega odmerka, odmerek razdelite na dve injiciranji ali uporabite nov peresnik.
Having too low or too high blood sugar or sight problems can affect your ability to drive and use tools or machines. 
Prenizek ali previsok krvni sladkor ali težave z vidom lahko vplivajo na sposobnost vožnje, uporabe orodij in upravljanja s stroji.
• You have just started insulin treatment or changed to another insulin - if low blood sugar occurs, it may be more likely to happen in the morning. 
• Ste pravkar začeli zdravljenje z insulinom, ali ste prešli na drug insulin - če se pojavi nizek krvni sladkor, se to verjetneje zgodi zjutraj.
• Check your blood sugar and then inject your next dose at the usual time. 
• Izmerite krvni sladkor in nato injicirajte naslednji odmerek ob običajnem času.
Using a new sterile needle for each injection also minimizes the risk of contamination and infection. 
Uporaba nove, sterilne igle za vsako injiciranje zmanjša tudi tveganje za onesnaženje in okužbo.
DoubleStar) are not bioequivalent and are therefore not interchangeable without dose adjustment. 
Toujeo DoubleStar) nista bioekvivalentna in zato nista medsebojno zamenljiva brez prilagoditve odmerka.